Only 6 percent of patients carried a concerning DPYD variant, but nearly two-thirds of them were later hospitalized after ...

A combination of BRAF and MEK inhibitors plus immunotherapy improved progression-free but not overall survival, compared to dual immune checkpoint blockade.

The Australian company is betting the radionuclide could be an option for patients with HER2-expressing solid tumors who can't tolerate other treatments.

The French company is designing a Phase IIb program to validate the biomarker, which could identify the 30 percent of patients likely to respond to the antibody.

At ASCO, researchers presented results of Phase I trials evaluating combinations of KRAS G12C inhibitors, EGFR inhibitors, and chemotherapy in colorectal cancer.

Researchers are trying to better understand how co-mutations and PD-L1 expression impact response to single-agent KRAS G12C ...

Investigators aim to establish an optimal dose and explore CER-1236's safety and preliminary anti-tumor activity.

Two studies presented at ASCO's annual meeting used ctDNA testing to determine which patient might benefit from anti-EGFR retreatment.

UniQure said it has aligned with the FDA on components of a statistical analysis plan for a registrational trial of AMT-130.

A combination of Enhertu and Perjeta nearly doubled progression-free survival compared to standard therapy in data presented ...

AstraZeneca's camizestrant and Pfizer's vepdegestrant extended progression-free survival in trials in advanced ESR1-mutated breast cancer.

Researchers at ASCO reviewing data from the ATOMIC trial said they will change practice based on the results but questioned ...